Back to School: How biopharma can reboot drug development. Access exclusive analysis here

AVE1642: Phase I data

In an open-label, dose-escalation Phase I trial in 14 patients, IAVE1642 was well

Read the full 133 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE